AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Date Added
June 22nd, 2012
PRO Number
Pro00016822
Researcher
Jacqueline Kraveka

List of Studies


Keywords
Adolescents, Cancer, Cancer/Leukemia, Pediatrics
Summary

To collect information about the patient's leukemia and to seek the optimal treatment for children with ALL based on the individual level of risk of the cancer coming back after treatment. The risk groups are defined as a result of recent research conducted by the Children's Oncology Group (COG). We would like to learn if the use of an experimental intrathecal therapy (ITT), which has been given to many people with ALL and has been well tolerated, would be better at preventing relapse in the central nervous system and improve disease outcomes in children with High Risk ALL.

Institution
MUSC
Recruitment Contact
Jacqueline Kraveka
843-792-2957
kravekjm@musc.edu

Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

Date Added
December 17th, 2002
PRO Number
Pro00136123
Researcher
Michelle Hudspeth

List of Studies


Keywords
Adolescents, Cancer, Transplant
Summary

The Center for International Blood and Marrow Transplant Research (CIBMTR ) keeps a research database. It uses this database to collect and study the medical data for patients that have received Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries. It also collects and studies data from donors who give bone marrow or peripheral blood stem cells (PBSCs). These therapies are used to treat cancer and other diseases. The purpose of this study is to add more data to the database. Participants will have medical data (data about their disease, transplant or cellular therapy) collected before and after transplant cellular therapy, and once a year afterwards for life.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

Date Added
December 17th, 2002
PRO Number
Pro00136076
Researcher
Michelle Hudspeth

List of Studies


Keywords
Adolescents, Cancer, Transplant
Summary

The primary purpose of the Research Sample Repository is to make blood samples available for research studies related to histocompatibility and hematopoietic cell transplantation (HCT) or other cellular therapy.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu



-- OR --